Titlebook: Biology and Management of Multiple Myeloma; James R. Berenson Book 2004 Springer Science+Business Media New York 2004 Staging.anemia.bone

Offset

Fallibility

Keratectomy

Remission Maintenance in Multiple Myeloma,eau”— phase of variable length, a cytokinetically quiescent state . in which myeloma cell proliferation is balanced by myeloma cell death. Complete or partial remission is not an absolute prerequisite for a plateau phase, which can be observed in patients whose best response to induction treatment i

鋼筆尖

圖畫文字

Renal Diseases Associated With Multiple Myeloma and Related Plasma Cell Dyscrasias,ni syndrome (AFS) represent a group of disorders characterized by the presence of monoclonal plasma cells in bone marrow and their homogeneous immunoglobulin products—i.e., M proteins—in serum, urine, or both .. These immunoglobulin components can be nephrotoxic, as evidenced by their propensity to

scrape

Surgeon

New Therapeutic Approaches to Myeloma,icians have found that the most effective drugs for the treatment of myeloma belong to the following pharmacologic classes: alkylating agents (melphalan, cyclophosphamide, 1,3-bis-[2-chloroethyl]-1-nitrosurea [BCNU]), topoisomerase II inhibitors (doxorubicin and etoposide), glucocorticoids (predniso

碎片

hallow

978-1-61737-143-1Springer Science+Business Media New York 2004

攤位

Biology and Management of Multiple Myeloma978-1-59259-817-5Series ISSN 2364-1134 Series E-ISSN 2364-1142